Complement C5
Sign in to saveAlso known as C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4, C5a anaphylatoxin, C5, anaphylatoxin C5a analog, prepro-C5, complement component 5
mammalian protein found in Homo sapiens
Protein · UniProt
Complement C5
- Gene
- C5
- Organism
- Homo sapiens (Human)
- Length
- 1,676 aa
- Molecular mass
- 188,305 Da
- Evidence
- 1: Evidence at protein level
Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:6554279). Activated downstream of classical, alternative, lectin and GZMK complement pathways (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:39914456, PubMed:39814882, PubMed:6554279)
Swiss-Prot (reviewed) · via UniProt
Research
8,590 papers- Using genetics to explore complement C5 as a druggable protein in periodontitis.Frontiers in immunology · 2024
- An inhibitor of complement C5 provides structural insights into activation.Proceedings of the National Academy of Sciences of the United States of America · 2020
- Complement C5/C5a in the diagnosis and treatment of Graves' ophthalmopathy: A Mendelian randomized study.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
- Structure and function of complement C5 convertase enzymes.Biochemical Society transactions · 2002
- A small-molecule inhibitor of C5 complement protein.Nature chemical biology · 2019
via PubMed
Clinical Trials
35 registered- PHASE1/PHASE2UNKNOWNA Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNHCARE Pharma Shanghai Ltd. · NCT05539248
- PHASE3ACTIVE_NOT_RECRUITINGSafety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia GravisAlexion Pharmaceuticals, Inc. · NCT05556096
- PHASE2COMPLETEDCoversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)AKARI Therapeutics · NCT02591862
- PHASE3RECRUITINGPK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia GravisAlexion Pharmaceuticals, Inc. · NCT06607627
- PHASE1/PHASE2RECRUITINGA First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 InhibitorRegeneron Pharmaceuticals · NCT07187401
- PHASE2TERMINATEDStudy of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as MonotherapyAlexion Pharmaceuticals, Inc. · NCT04170023